New Years' Resolutions

If a panel of analysts are correct, the coming year will bring the reintroduction of Biogen-Idec's Tysabri, approval of Merck's human papilloma virus vaccine Gardasil and a continued stalemate over generic biologics. We asked top pharmaceutical analysts to weigh in on the events they think will move the market in 2006.

By Kate Rawson

The coming year will bring Food & Drug Administration approval of a first-ever cancer vaccine, the reintroduction of a withdrawn...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Agency Leadership

More from Pink Sheet